Immunogenetic aspects of etiopathogenesis of rheumatoid arthritis: the role of - 308 G/A tumor necrosis factor α promoter polymorphism
Authors:
P. Němec
Authors place of work:
Revmatologická ambulance II. interní kliniky FN u sv. Anny v Brně a LF MU Brno
Published in the journal:
Čes. Revmatol., 15, 2007, No. 1, p. 25-33.
Category:
Summaries of Doctoral Dissertations
Summary
Introduction.
Rheumatoid arthritis (RA) is a polygenic disorder and genetic determination can contribute to both susceptibility and severity of the disease. Tumor necrosis factor (TNF) α, a potent pro-inflammatory cytokine, plays a key role in the pathogenesis of RA. Several alleles from the HLA-DRB1 locus have been often found to be associated with RA. Thereby, the interest is focused on polymorphisms of the TNF α gene, which is located within the highly polymorphic MHC class III region next to HLA-DR locus on chromosome 6 (6p21.3). TNF α concentration is increased in plasma as well as in synovial fluid from patients with RA. Production of TNF α may be related to the polymorphisms in the TNF α gene. In patients with RA, cardiovascular diseases are responsible for death in 35 – 50 % cases, whereas in general adult population in about 20 - 25 % cases. This increased risk may be associated with RA-specific risk factors such as hyperhomocysteinemia, disease-related dyslipidemia, vascular inflammation, or increased levels of TNF α. It is well known that TNF α can play a role in the process of atherosclerosis. The -308 G/A TNF α promoter polymorphism was demonstrated to associate with obesity, dyslipidemia, insulin resistance, and hypertension - risk factors for coronary heart disease. The aim of the study was to analyze literature data, select a candidate gene for RA, and demonstrate possible association between its polymorphism and risk for onset and severity of RA with respect to several features of the disease.
Methods.
A total of 130 patients with RA according to the American College of Rheumatology revised criteria were recruited into the study. The disease duration was at least 2 years. Patients were classified into four groups according to the grade of radiographic progression of the hand and wrist (Steinbrocker radiographic score: grade 1: non-erosive RA – 15 patients, grade II – IV: erosive RA – 114 patients). Control group consisted of 150 subjects with similar age and sex distribution.
Results.
We observed no differences in genotype distributions and allelic frequencies of – 308 G/A TNF α promoter polymorphism between RA patients and control group. Significant difference was found for GG genotype in contrast to other genotypes (AA + AG) in – 308 G/A TNFα promotor polymorphism between patients with non-erosive and erosive diseases. In patients with erosive disease, GG genotype was more frequent (47.0 % vs. 74.6 %; OR = 3.35; 95% CI 0.99 – 11.45; P = 0.03). Statistically significant difference was also in allelic frequencies (Pa = 0.05). The difference between groups of patients with respect to genotype distribution was on the borderline of significance (Pg = 0.06). Comparing non-erosive patients and patients with the worst grade of radiographic involvement of the hand and wrist (grade IV), the prevalence of GG genotype was more than 6-fold higher in patients with erosive RA (40.0 % vs. 87.0 %; OR = 6.29; 95 % CI 1.19–36.43; P = 0,01). The difference in allelic frequencies of – 308 G/A TNF α polymorphism between groups of patients with different disabilities according to HAQ was found. Higher frequency of allele G was found in patients with more severe disability (HAQ > 1.00) (Pa = 0.035). Moreover, comparing genotype GG with other genotypes (AA + AG) of – 308 G/A TNF α polymorphism, we found increased presence of genotype GG in patients with increased (> 3.00 mmol/l) in contrast to patients with normal (1.00 – 3.00 mmol/l) plasma level of LDL cholesterol (OR = 2.29; 95% CI 0.94 – 5.63; P = 0.035). Statistically significant difference between those groups was also found for alellic frequencies (Pa = 0.047). Conclusion: The results of this work indicate an association of – 308 G/A TNF α polymorphism with more severe course of RA. Moreover, potential association of this polymorphism with plasma level of LDL cholesterol in RA patients was found.
Key words:
gene, polymorphism, rheumatoid arthritis, TNF α
Zdroje
1. Lawrence RC, Helmick GG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculosceletal disorders in the United States. Arthritis Rheum 1998;41: 778–99.
2. MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000; Jan; 43: 30–7.
3. Winchester R. The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 1994; 56 : 389–466.
4. Stastny P. Association of B cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978; 298: 869–71.
5. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis. Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38–46.
6. Verpoort KN, van Gaalen FA, van der Helm-van Mil AHM, et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum 2005; 10: 3058–62.
7. Zanelli E, Breedveld FC, de Vries RRP. HLA Class II association with rheumatoid arthritis. Facts and interpretations. Hum Immunol 2000; 61: 1254–61.
8. Yamada R, Tanaka T, Ohnishi Y, et al. Identification of 142 single nucleotide polymorphisms in 41 candidate genes for rheumatoid arthritis in the Japanese population. Hum Genet 2000; 106: 293–7.
9. Lin CH, Cho CL, Tsai WC, et al. Inhibitors of kB-like gene polymorphisms in rheumatoid arthritis.Immunol Lett 2006; 105: 193–7.
10. Iwamoto T, Ikari K, Nakamura T, et al. Association between PADI4 and rheumatoid arthritis: a meta-analysis. Rheumatology (Oxford) 2006; 45: 804–7.
11. Ruuls SR, Sedgwick JD. Unliking Tumor necrosis factor biology from the major histocompatibility complex: lessons from human genetics and animal models. Am J Hum Genet 1999; 65: 294–30.
12. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411–52.
13. Ota M, Katsuyama Y, Kimura A, et al. A second susceptibility gene for developing rheumatoid arthritis in the human MHC is localized within a 70-kb interval telomeric of the TNF genes in the HLA class III region. Genomics 2001; 71: 263–70.
14. Hajeer AH, Hutchinson IV. Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Human Immunol 2001; 62: 1191–9.
15. Cvetkovic JT, Wallberg-Jonsson S, Stegmayr B, et al. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1, and IL-1Ra genes. J Rheumatol 2002; 29: 212–9.
16. Wilson AG, de Vries N, van de Putte LB, Duff GW. A tumor necrosis factor alpha polymorphism is not associated with rheumatoid arthritis. Ann Rheum Dis 1995; 54: 601–3.
17. Brinkman BM, Huizinga TW, Kurban SS, et al. Tumor necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility, or severity of disease? Br J Rheumatol 1997; 36: 516–21.
18. Barton A, Platt H, Salway F, et al. Polymorphism in the tumor necrosis factor gene are not associated with severity of inflammatory polyarthritis. Ann Rheum Dis 2004; 63: 280–4.
19. Danis VA, Millington M, Hyland V, et al. Increased frequency of the uncommon allele of a tumor necrosis factor alpha polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 1995;12: 127–33.
20. Rodriguez-Carreon AA, Zuniga J, Hernandez-Pachelo G, et al. Tumor necrosis factor-alpha promoter polymorphism contributes independently to HLA alleles in severity of rheumatoid arthritis in Maxicans. J Autoimmun 2005; 24: 63–8.
21. Pawlik A, Florczak M, Ostanek L, et al. TNF–α – 308 promoter polymorphism in patients with rheumatoid arthritis. Scand J Rheumatol 2005; 34: 22–6.
22. Vinasco J, Beraun Y, Nieto A, et al. Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 1997; 49: 74–8.
23. Bouma G, Xia B, Crusius JB, et al. Distribution of four polymorphisms in the tumor necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1996; 103: 391–6.
24. Louis E, Franchimont D, Piron A, et al. Tumor necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysacharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113: 401–6.
25. Mycko MP, Kowalski W, Kwinkowski M, et al. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymfotoxin-alpha. J Neuroimmunol 1998; 84: 198–206.
26. Cuenca J, Cuchacovich M, Perez C, et al. The – 308 polymorphism in the tumor necrosis factor (TNF) gene promoter region and ex vivo lipopolysacharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis. Rheumatology 2003; 42: 308–13.
27. Mugnier B, Balandraud N, Darque A, et al. Polymorphism at position –308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003; 48: 1849–52.
28. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, et al. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 2005; 4: 153–61.
29. Sookoian S, Garcia SI, Gianotti TF, et al. The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with hypertension in adolescents harboring the metabolic syndrome. Am J Hypertens 2005; 18: 1271–5.
30. Sookoian SC, Gonzalez C, Pirola CJ. Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome. Obes Res 2005; 13: 2122–31.
31. Um JY, Park JH, Kim HM. Gene polymorphisms in tumor necrosis factor locus and waist-hip ratio in obese Koreans. Clin Chim Acta 2003; 338: 117–22.
32. Dalziel B, Gosby AK, Richman RM, et al. Association of the TNF-alpha -308 G/A promoter polymorphism with insulin resistance in obesity. Obes Res 2002; 10: 401–7.
33. Ischii T, Hirose H, Saito I, et al. Tumor necrosis factor alpha gene G-308A polymorphism, insulin resistance, and fasting plasma glucose in young, older, and diabetic Japanese men. Metabolism 2000; 49: 1616–8.
34. Lee SC, Pu YB, Tomas GN, et al. Tumor necrosis factor alpha gene G-308A polymorphism in the metabolic syndrome. Metabolism 2000; 49: 1021–4.
Štítky
Dermatology & STDs Paediatric rheumatology RheumatologyČlánok vyšiel v časopise
Czech Rheumatology
2007 Číslo 1
Najčítanejšie v tomto čísle
- Muscle inflammatory processes and their clinical manifestations in patients with polymyositis and dermatomyositis
- Possibilities of immunochemical detection of cartilage type II collagen degradation
- Potentional role of selected biomarkers in the evaluation and pathogenesis of osteoarthritis and rheumatoid arthritis
- Immunogenetic aspects of etiopathogenesis of rheumatoid arthritis: the role of - 308 G/A tumor necrosis factor α promoter polymorphism